Kathleen A. Fairman

1.5k total citations
56 papers, 963 citations indexed

About

Kathleen A. Fairman is a scholar working on Public Health, Environmental and Occupational Health, Economics and Econometrics and Geriatrics and Gerontology. According to data from OpenAlex, Kathleen A. Fairman has authored 56 papers receiving a total of 963 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Public Health, Environmental and Occupational Health, 14 papers in Economics and Econometrics and 10 papers in Geriatrics and Gerontology. Recurrent topics in Kathleen A. Fairman's work include Health Systems, Economic Evaluations, Quality of Life (10 papers), Pharmaceutical Practices and Patient Outcomes (10 papers) and Opioid Use Disorder Treatment (8 papers). Kathleen A. Fairman is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (10 papers), Pharmaceutical Practices and Patient Outcomes (10 papers) and Opioid Use Disorder Treatment (8 papers). Kathleen A. Fairman collaborates with scholars based in United States, Israel and Ivory Coast. Kathleen A. Fairman's co-authors include Brenda R. Motheral, David A. Sclar, Alyssa M. Peckham, Maureen J. Lage, Rochelle Henderson, Kellie J. Goodlet, Cathryn A. Carroll, Emily R. Cox, Dawn I. Velligan and Mark E. Frisse and has published in prestigious journals such as Clinical Infectious Diseases, Medical Care and Health Psychology.

In The Last Decade

Kathleen A. Fairman

54 papers receiving 905 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kathleen A. Fairman United States 15 314 234 174 172 158 56 963
Jaana E. Martikainen Finland 19 319 1.0× 107 0.5× 294 1.7× 155 0.9× 263 1.7× 44 1.3k
Michael Johnsrud United States 18 319 1.0× 203 0.9× 96 0.6× 143 0.8× 385 2.4× 40 1.2k
Yu‐Jung Jenny Wei United States 19 86 0.3× 107 0.5× 209 1.2× 146 0.8× 151 1.0× 56 976
Gabriel Sanfélix‐Gimeno Spain 24 217 0.7× 279 1.2× 154 0.9× 152 0.9× 271 1.7× 92 1.6k
Katja Hermann Germany 15 131 0.4× 189 0.8× 237 1.4× 122 0.7× 95 0.6× 41 914
Pamela C. Heaton United States 23 147 0.5× 151 0.6× 173 1.0× 301 1.8× 137 0.9× 83 1.4k
Wei‐Hsuan Lo‐Ciganic United States 19 95 0.3× 118 0.5× 488 2.8× 143 0.8× 91 0.6× 100 1.2k
Susan Ogle Australia 15 189 0.6× 91 0.4× 65 0.4× 305 1.8× 131 0.8× 27 1.0k
Kem P. Krueger United States 10 100 0.3× 249 1.1× 57 0.3× 227 1.3× 82 0.5× 26 693
Connie Mah Trinacty United States 18 112 0.4× 221 0.9× 266 1.5× 111 0.6× 83 0.5× 36 1.2k

Countries citing papers authored by Kathleen A. Fairman

Since Specialization
Citations

This map shows the geographic impact of Kathleen A. Fairman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathleen A. Fairman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathleen A. Fairman more than expected).

Fields of papers citing papers by Kathleen A. Fairman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathleen A. Fairman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathleen A. Fairman. The network helps show where Kathleen A. Fairman may publish in the future.

Co-authorship network of co-authors of Kathleen A. Fairman

This figure shows the co-authorship network connecting the top 25 collaborators of Kathleen A. Fairman. A scholar is included among the top collaborators of Kathleen A. Fairman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathleen A. Fairman. Kathleen A. Fairman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Larson, Suzanne, et al.. (2023). Finding our Voice: Evaluation of Goal Setting Using the Habits of Preceptors Rubric in Terms of Focus, “SMARTness,” and Impact. Journal of Continuing Education in the Health Professions. 44(3). 162–170. 1 indexed citations
2.
3.
Fairman, Kathleen A., et al.. (2021). Use of Learning Management System Data to Predict Student Success in a Pharmacy Capstone Course. American Journal of Pharmaceutical Education. 86(4). 8594–8594. 6 indexed citations
4.
Fairman, Kathleen A., et al.. (2020). Physical and psychological functioning in veterans with diabetes: Disease-related versus service-related effects.. Health Psychology. 40(1). 1–10. 2 indexed citations
5.
Goodlet, Kellie J., et al.. (2020). Association of Antibiotic Treatment Duration With Recurrence of Uncomplicated Urinary Tract Infection in Pediatric Patients. Annals of Pharmacotherapy. 54(8). 757–766. 7 indexed citations
6.
Peckham, Alyssa M., et al.. (2019). High-risk opioid prescribing trends in the outpatient setting prior to issuance of federal guidance. Preventive Medicine Reports. 15. 100892–100892. 4 indexed citations
7.
Fairman, Kathleen A., et al.. (2019). Joint effects of advancing age and number of potentially inappropriate medication classes on risk of falls in Medicare enrollees. BMC Geriatrics. 19(1). 194–194. 13 indexed citations
8.
Molina, Kyle C., Kathleen A. Fairman, & David A. Sclar. (2018). Concomitant use of opioid medications with triptans or serotonergic antidepressants in US office-based physician visits. Drug Healthcare and Patient Safety. Volume 10. 37–43. 14 indexed citations
9.
Fairman, Kathleen A., et al.. (2018). Use of power-law analysis to predict abuse or diversion of prescribed medications: proof-of-concept mathematical exploration. BMC Research Notes. 11(1). 523–523. 1 indexed citations
10.
Fairman, Kathleen A., et al.. (2017). Provision of Lifestyle Counseling and the Prescribing of Pharmacotherapy for Hyperlipidemia Among US Ambulatory Patients: A National Assessment of Office-Based Physician Visits. American Journal of Cardiovascular Drugs. 18(1). 65–71. 9 indexed citations
11.
Peckham, Alyssa M., Kathleen A. Fairman, & David A. Sclar. (2017). Prevalence of Gabapentin Abuse: Comparison with Agents with Known Abuse Potential in a Commercially Insured US Population. Clinical Drug Investigation. 37(8). 763–773. 39 indexed citations
12.
Fairman, Kathleen A., et al.. (2017). Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice. Therapeutics and Clinical Risk Management. Volume 13. 957–965. 14 indexed citations
13.
Fairman, Kathleen A., et al.. (2015). Association of Medication Persistency with Route of Administration and Patient Cost-Sharing: Analysis of Commonly Used Biologics. Value in Health. 18(7). A650–A650. 2 indexed citations
14.
Fairman, Kathleen A.. (2012). Health Care Research Done Right: A Journal Editor Shares Practical Tips and Techniques for High Quality and Efficiency. 2 indexed citations
15.
Curtiss, Frederic R. & Kathleen A. Fairman. (2008). Diabetes Drug Therapy -- First Do No Harm. Journal of Managed Care Pharmacy. 14(7). 658–660. 1 indexed citations
16.
Fairman, Kathleen A. & Brenda R. Motheral. (2003). Do Decision-Analytic Models Identify Cost-Effective Treatments? A Retrospective Look at Helicobacter Pylori Eradication. Journal of Managed Care Pharmacy. 9(5). 430–440. 7 indexed citations
17.
Fairman, Kathleen A., Brenda R. Motheral, & Rochelle Henderson. (2003). Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clinical Therapeutics. 25(12). 3147–3161. 53 indexed citations
18.
Motheral, Brenda R. & Kathleen A. Fairman. (2001). Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization. Medical Care. 39(12). 1293–1304. 127 indexed citations
19.
Fairman, Kathleen A.. (2000). The effect of new and continuing prescription drug use on cost: A longitudinal analysis of chronic and seasonal utilization. Clinical Therapeutics. 22(5). 641–652. 6 indexed citations
20.
Motheral, Brenda R., et al.. (2000). Role of pharmacoeconomics in drug benefit decision-making: Results of a survey. 35(5). 412–421. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jaana E. Martikainen Breakdown of academic impact, for papers by Michael Johnsrud Breakdown of academic impact, for papers by Yu‐Jung Jenny Wei Breakdown of academic impact, for papers by Gabriel Sanfélix‐Gimeno Breakdown of academic impact, for papers by Katja Hermann Breakdown of academic impact, for papers by Pamela C. Heaton Breakdown of academic impact, for papers by Wei‐Hsuan Lo‐Ciganic Breakdown of academic impact, for papers by Susan Ogle Breakdown of academic impact, for papers by Kem P. Krueger Breakdown of academic impact, for papers by Connie Mah Trinacty
Rankless by CCL
2026